ZNTL

Zentalis Pharmaceuticals, Inc.

ZNTL | $13.015 0.42% 0.42% 450K

(0.0% 1d) (-4.3% 1m) (-39.5% 1y) (0.0% 2d) (0.0% 3d) (2.3% 7d) (-55.77% volume)
Earnings Calendar: 2023-11-08
Market Cap: $ 923,546,547
http://www.zentalis.com
Sec Filling | Patents | 62 employees

(US) Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.

breast cancer cancer treatment

add to watch list Paper trade email alert is off

Press-releases

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
ZNTL | $13.015 0.42% 0.42% 450K

Health Technology

| -16.77% | O: -6.85% H: 7.84% C: 7.35%
pharmaceuticals preclinical meeting

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-01 (Crawled : 22:00) - globenewswire.com
ZNTL | $13.015 0.42% 0.42% 450K

Health Technology

| -15.61% | O: 1.4% H: 0.0% C: 0.0%
nasdaq pharmaceuticals grants

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-01 (Crawled : 23:00) - globenewswire.com
ZNTL | $13.015 0.42% 0.42% 450K

Health Technology

| Email alert Add to watchlist
nasdaq pharmaceuticals grants

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Published: 2024-02-28 (Crawled : 12:00) - globenewswire.com
ZNTL | $13.015 0.42% 0.42% 450K

Health Technology

| -11.62% | O: 3.6% H: 18.57% C: 1.64%
pharmaceuticals

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
ZNTL | $13.015 0.42% 0.42% 450K

Health Technology

| -7.67% | O: 2.41% H: 3.88% C: 2.01%
year pharmaceuticals financial results

Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
Published: 2024-02-13 (Crawled : 12:00) - globenewswire.com
ZNTL | $13.015 0.42% 0.42% 450K

Health Technology

| 13.04% | O: -4.7% H: 1.55% C: -1.19%
conference life pharmaceuticals sciences

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-01 (Crawled : 22:00) - globenewswire.com
ZNTL | $13.015 0.42% 0.42% 450K

Health Technology

| 11.21% | O: -2.14% H: 2.19% C: 1.31%
nasdaq pharmaceuticals grants

Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
Published: 2024-01-25 (Crawled : 12:00) - globenewswire.com
ZNTL | $13.015 0.42% 0.42% 450K

Health Technology